Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers
This article was originally published in The Gray Sheet
Executive Summary
Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.
You may also be interested in...
Bard R&D To Triple In Three Years Through Savings From Plant Consolidation
Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.
Bard R&D To Triple In Three Years Through Savings From Plant Consolidation
Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.
Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO
Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.